Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects With Schizophrenia

NCT05110157 is registered in ClinicalTrials.gov with Neurocrine Biosciences as lead sponsor.

NCT NCT05110157
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05110157 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects With Schizophrenia
Lead sponsor
Neurocrine Biosciences
Phase
Phase 3
Overall status
Completed
Start date
November 29, 2021
Completion date
February 18, 2025
Enrollment
442 (actual)
Sites
87

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia